Protalix Biotherapeutics Inc Share Price TEL AVIV STOCK EXCHANGE
Stocks
US74365A1016
Pharmaceuticals
| Market Cap | 205M 0 176M 165M 151M 284M 19.56B 285M 1.96B 765M 9.87B 768M 752M 32.74B | P/E 2026 * |
13.4x | P/E 2027 * | 46.2x |
|---|---|---|---|---|---|
| Enterprise Value | 205M 0 176M 165M 151M 284M 19.56B 285M 1.96B 765M 9.87B 768M 752M 32.74B | EV / Sales 2026 * |
2.56x | EV / Sales 2027 * | 3x |
| Free-Float |
96.12% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Protalix Biotherapeutics Inc
| 1 day | -1.13% |
| Manager | Title | Age | Since |
|---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 59 | 29/06/2019 |
Gilad Mamlok
DFI | Director of Finance/CFO | 57 | 23/08/2025 |
Ori Kalid
CTO | Chief Tech/Sci/R&D Officer | - | 31/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amos Bar Shalev
BRD | Director/Board Member | 73 | 30/06/2008 |
Aharon Schwartz
BRD | Director/Board Member | 83 | 31/10/2014 |
Dror Bashan
BRD | Director/Board Member | 59 | 29/06/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | -11.89% | - | - | 205M | |
| -0.13% | -6.44% | +60.34% | +112.06% | 1,047B | |
| +0.85% | -0.81% | +51.29% | +63.13% | 646B | |
| -1.03% | -3.58% | +21.43% | +73.10% | 451B | |
| -1.46% | -4.50% | +37.80% | +37.41% | 355B | |
| -0.72% | -2.89% | +22.32% | +36.62% | 291B | |
| -1.19% | -2.21% | +1.53% | +10.79% | 252B | |
| -1.05% | -1.57% | +50.30% | +66.55% | 234B | |
| +0.08% | -1.78% | -17.64% | -54.36% | 203B | |
| -2.14% | -0.30% | +28.95% | +86.27% | 181B | |
| Average | -0.79% | -2.68% | +28.48% | +47.95% | 406.59B | |
| Weighted average by Cap. | -0.46% | -3.46% | +38.17% | +65.00% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 79.8M 0 68.76M 64.47M 58.85M 111M 7.63B 111M 765M 298M 3.85B 300M 293M 12.77B | 68.19M 0 58.76M 55.1M 50.29M 94.75M 6.52B 95.05M 654M 255M 3.29B 256M 250M 10.91B |
| Net income | 15.38M 0 13.25M 12.42M 11.34M 21.36M 1.47B 21.43M 147M 57.5M 742M 57.73M 56.47M 2.46B | 4.46M 0 3.85M 3.61M 3.29M 6.2M 427M 6.22M 42.78M 16.69M 215M 16.76M 16.39M 714M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
